tiprankstipranks
Advertisement
Advertisement
OSTX Earnings this Week: How Will it Perform?
PremiumPre-EarningsOSTX Earnings this Week: How Will it Perform?
3M ago
OS Therapies bolsters funding to advance OST-HER2 program
Premium
Company Announcements
OS Therapies bolsters funding to advance OST-HER2 program
3M ago
Regulatory Momentum and De-Risked Path to Accelerated Approval Support Buy Rating on OST-HER2 Osteosarcoma Program
Premium
Ratings
Regulatory Momentum and De-Risked Path to Accelerated Approval Support Buy Rating on OST-HER2 Osteosarcoma Program
3M ago
OS Therapies Raises Capital Through Warrant Inducement Agreements
PremiumCompany AnnouncementsOS Therapies Raises Capital Through Warrant Inducement Agreements
6M ago
Promising Outlook for OS Therapies: Buy Rating Backed by Positive FDA Meeting and Strategic Positioning
Premium
Ratings
Promising Outlook for OS Therapies: Buy Rating Backed by Positive FDA Meeting and Strategic Positioning
7M ago
OS Therapies price target lowered to $17 from $18 at Lake Street
Premium
The Fly
OS Therapies price target lowered to $17 from $18 at Lake Street
8M ago
Promising Regulatory Progress and Market Potential Justify Buy Rating for OS Therapies’ OST-HER2
PremiumRatingsPromising Regulatory Progress and Market Potential Justify Buy Rating for OS Therapies’ OST-HER2
9M ago
Strategic Regulatory Advances and Promising Clinical Data Drive Buy Rating for OS Therapies
Premium
Ratings
Strategic Regulatory Advances and Promising Clinical Data Drive Buy Rating for OS Therapies
9M ago
OS Therapies Files Prospectus for Stock Resale
Premium
Company Announcements
OS Therapies Files Prospectus for Stock Resale
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100